Daratumumab is an anti-CD38 monoclonal antibody approved for use in multiple myeloma
in 2015 and under investigation for use in light-chain amyloidosis. We report a case of a …

Purpose: We describe a case of bilateral angle closure glaucoma following the infusion of
daratumumab, a monoclonal antibody used to treat relapsing multiple myeloma. Methods …

Discussion Daratumumab is an IgG1κ monoclonal antibody approved by the United States
Food and Drug Administration for the treatment of multiple myeloma as both monotherapy …

Purpose To report a case of daratumumab-induced bilateral angle closure glaucoma and
myopia that showed no recurrence after repeated drug administration with prophylactic …

Methods| Under statutory authority pursuant to public health, no approval from institutional
review boards or informed consent was required for this case series analysis. We reviewed …

Daratumumab-containing regimens are an effective treatment for advanced cases of
multiple myeloma. Overall, daratumumab has a favourable safety profile, although rare side …

Discussion Specific ophthalmic toxicity is a relatively new observation in relation to myeloma
treatment. However, it is described as an important adverse event associated with new …

Purpose To describe an unprecedented case of transient myopic shift induced by a
chemotherapeutic agent, daratumumab. Observations A 43-year-old emmetropic female …

Leukoencephalopathy in the setting of multiple myeloma (MM) is a rare demyelinating
condition, with few reported cases in literature. Daratumumab is a CD38 targeted …

PURPOSE Daratumumab is an anti-CD38 monoclonal antibody used to treat multiple
myeloma and light chain amyloidosis. Because daratumumab may cause reactions after …